Current stock page

Stock Analysis

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis

Agios Pharmaceuticals, Inc. (AGIO) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

AGIO Stock Analysis Summary

Agios Pharmaceuticals, Inc. (AGIO) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

AGIO at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$31.59
AIQ Score56/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.89B
P/E Ratio (TTM)-5
Forward P/E—
EPS (Q3 FY2026)-$1.09
Revenue (Q3 FY2026)$55.39M
Dividend Yield (TTM)0.00%
Beta0.93
Volume371.34K
52-week range$22.24-$46.00
RSI 1446.26
50-Day SMA$33.09
200-Day SMA$31.85
Analyst Price Target$35.00
Next EarningsFeb 11, 2027
As of Nov 13, 2026 · Market close

AGIOAgios Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$31.59−$0.17 (−0.54%)

Latest quote

  • Momentum
    61
  • Value
    52
  • Quality
    58
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

AGIO Stock Analysis Summary

Agios Pharmaceuticals, Inc. (AGIO) currently has an AIQ Score of 56/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, AGIO has AIQ Score of 56/100 with Momentum base of 61/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.

Healthcare · -0.54% stock move · AGIO classified in Biotechnology.

Current Evidence

NeutralAGIO is in a neutral AIQ regime; Momentum is the strongest visible factor at 61/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is AGIO Bullish or Bearish Right Now?

AGIO currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +10.79% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 47/100.
  • - Price is -0.80% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (35 vs 3).

Current Consensus

AGIO's Technical Analysis Consensus is currently Strong Sell, with 3 buy, 8 neutral, and 35 sell votes. AGIO's 14-day RSI is 46.26, which places the stock in a neutral momentum range. AGIO's beta is 0.93, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in AGIO?

The largest recent change in AGIO is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-2.0
Quality
+1.0
Risk
-1.0

What Would Change the AGIO Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

AGIO Decision Framework

Public evidence layers, setup checks, and risk context for Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis

Agios Pharmaceuticals, Inc. has an AIQ Score of 56/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 0.93, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextAGIO is in a Neutral AIQ regime with score 56/100.
Signal ConflictThe primary conflict is that momentum leads at 61/100 while risk lags at 47/100.
Factor EvidenceMomentum 61/100 · Value 52/100 · Quality 58/100 · Risk 47/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Momentum is the strongest factor at 61/100.

TimingWait

Momentum is 61/100 and RSI (14) is 46.3.

Regime fitWait

AGIO is in a Neutral regime at 56/100.

Risk controlFail

Risk factor is 47/100 with beta 0.93 and annual volatility 79.96%.

ConflictPass

Current conflict: momentum leads at 61/100 while risk lags at 47/100.

AIQ Score
56/100
Price
$31.59
Beta
0.93
RSI (14)
46.3

AGIO Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

AGIO Fundamentals

AGIO valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$55.39M
Net income
-$65.05M
Free cash flow
-$60.42M
View full AGIO fundamental analysis

AGIO Technical Analysis

AGIO technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
46.26
Price vs SMA-50
-4.53%
View full AGIO technical analysis

AGIO Stock Catalysts

Track AGIO earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 11, 2027
Analyst target
$35.00
News items
4
View AGIO earnings and stock catalysts

AGIO Dividend Analysis

AGIO dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View AGIO dividend history and analysis

AGIO Financial Data

AGIO revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$55.39M
EPS
-$1.09
Periods
8
View AGIO financials

AGIO Risk Analysis

AGIO volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.93
Risk score
47/100
1Y volatility
79.96%
View AGIO risk analysis

AGIO Stock News

AGIO stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read AGIO stock news

AGIO vs Biotechnology Peers

Current peer cohort: AGIO · ALMS · AMLX · ANAB · ARGX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
AGIO
Current stock
56/10052/10061/10047/1000.0779.96%Current
ALMS
Alumis Inc.
20/100—13/10020/1000.65137.60%AGIO vs ALMS
AMLX
Amylyx Pharmaceuticals, Inc.
78/100—90/10048/1001.3587.03%AGIO vs AMLX
ANAB
AnaptysBio, Inc.
56/10074/10036/10046/1000.7864.84%AGIO vs ANAB
ARGX
argenx SE
74/10070/10074/10070/1000.2837.87%AGIO vs ARGX
Pairwise Compare links: ALMS · AMLX · ANAB · ARGXAGIO vs ALMSAGIO vs AMLXAGIO vs ANABAGIO vs ARGXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a AGIO stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for AGIO: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-5
As of Nov 13, 2026
Revenue growth
330.01%
Gross margin
91.94%
Current debt / equity
0.03
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$55.39M
Quarter net income
-$65.05M
Quarter free cash flow
-$60.42M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
46.26
MACD
-0.63

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
47/100
Beta
0.93
Annual volatility
79.96%
Max drawdown
-50.89%

AGIO Stock FAQ

What is AGIO stock price today?

Agios Pharmaceuticals, Inc.'s current stock price is $31.59. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is AGIO bullish or bearish right now?

AGIO's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is AGIO's market cap?

AGIO's market cap is $1.89B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is AGIO's current P/E ratio?

AGIO's current P/E ratio is -5 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is AGIO's RSI?

AGIO's 14-day RSI is 46.26 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is AGIO above its 50-day and 200-day moving averages?

AGIO is -4.53% from its 50-day SMA and -0.80% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is AGIO's next earnings date?

AGIO's next earnings date is currently listed as Feb 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does AGIO pay a dividend?

AGIO's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.